camptothecin has been researched along with Thrombopenia in 82 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.22) | 18.7374 |
| 1990's | 20 (24.39) | 18.2507 |
| 2000's | 32 (39.02) | 29.6817 |
| 2010's | 27 (32.93) | 24.3611 |
| 2020's | 2 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S | 1 |
| Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G | 1 |
| Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z | 1 |
| Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L | 1 |
| Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Shirasawa, M; Sone, H; Sugimoto, A; Sugita, K | 1 |
| Abe, T; Baba, J; Hirata, A; Ichikawa, K; Kikuchi, T; Kondo, R; Koya, T; Makino, M; Maruyama, Y; Sato, K; Shoji, S; Tanaka, H; Tanaka, J; Terada, M; Tsukada, H; Watanabe, S; Yoshizawa, H | 1 |
| Kawano, K; Matsukuma, K; Nasu, H; Nishio, S; Shimokawa, M; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T | 1 |
| Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
| Bekaii-Saab, T; Clinton, SK; Grever, MR; Kraut, EH; Martin, LK; Monk, P; Serna, D | 1 |
| Cheng, AL; Cho, DC; Chuadhary, I; Coleman, T; Ghalib, MH; Ghamande, S; Goel, S; Hsu, SC; Kuo, MW; Kwak, EL; Lin, CC; Mach, WB; Shapiro, GI; Silverman, MH; Tseng, Y; Yang, JC | 1 |
| Jeong, HY; Kang, DY; Kang, GH; Kim, SH; Lee, BS; Lee, ES; Lee, HY; Moon, HS; Sung, JK | 1 |
| Aster, RH; Curtis, BR; George, JN; Mirtsching, BC | 1 |
| Bertaut, A; Ghiringhelli, F; Ladoire, S; Lorgis, V; Rambach, L; Vincent, J | 1 |
| Fay, F; Greene, MK; Jarvis, GE; Johnston, PG; Kissenpfennig, A; Longley, DB; Majkut, J; McCloskey, KD; McLaughlin, KM; Schmid, D; Scott, CJ; Small, DM; Spence, S | 1 |
| Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA | 1 |
| Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI | 1 |
| Inoue, A; Ishimoto, O; Maemondo, M; Nukiwa, T; Sugawara, S | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Abiko, K; Abou-Taleb, HA; Baba, T; Hamanishi, J; Horikawa, N; Kitamura, S; Konishi, I; Koshiyama, M; Matsumura, N; Murakami, R; Taha, AA; Yamaguchi, K; Yamanoi, K | 1 |
| Mayo, MS; Smith, HJ; Watkins, JF; Williamson, SK | 1 |
| Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH | 1 |
| Amatu, A; Bernardo, G; Montagna, B; Pagella, C; Poggi, G; Pozzi, E; Quaretti, P; Sottotetti, F; Tagliaferri, B | 1 |
| Akiyama, Y; Ando, Y; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Bang, S; Chung, JB; Chung, MJ; Kim, YJ; Park, JY; Park, SW; Song, SY | 1 |
| Ahn, JB; Hong, YS; Kim, SH; Kim, SY; Kim, TW; Lee, KH; Lee, SH; Park, SH; Park, YS; Shin, SJ | 1 |
| Ariyoshi, Y; Fukuoka, M; Kakihata, K; Masatani, S; Sakata, Y; Shimazaki, M; Shiozawa, T; Tadokoro, J; Yamaguchi, F | 1 |
| Anderson, P; Bilton, SD; Chang, EL; Fontanilla, HP; Green, HL; Grosshans, DR; Hayes-Jordan, A; Mahajan, A; McAleer, MF; Pinnix, CC; Subbiah, V; Sulman, EP; Woo, SY | 1 |
| Hwang, JH; Kang, S; Lim, MC; Park, SY; Seo, SS; Yoo, HJ | 1 |
| Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Chen, DY; Zhao, WY | 1 |
| Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA | 1 |
| Atagi, S; Furuse, K; Hosoe, S; Kawaguchi, T; Kawahara, M; Naka, N; Ogawara, M; Okishio, K; Takemoto, Y; Tsuchiyama, T; Ueno, K | 1 |
| Agelaki, S; Androulakis, N; Aravantinos, G; Dimopoulos, MA; Foutzilas, G; Georgoulias, V; Giannakakis, T; Janninis, D; Kouroussis, C; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG | 1 |
| Hiroi, M; Hojyo, T; Isobe, K; Kimura, K; Ryo, H; Sano, G; Sugino, K; Toyama, K; Yamada, H | 1 |
| Eguchi, K; Goto, K; Hojo, F; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yoshimura, K | 1 |
| Akasu, T; Fujita, S; Hosokawa, A; Matsumura, Y; Moriya, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y | 1 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Hosaka, T; Ishida, H; Noguchi, H; Ogura, K; Ohmori, T | 1 |
| Shirao, K; Ura, T | 1 |
| Hochster, H; Mandeli, J; Muggia, FM; Plimack, ER; Runowicz, CD; Sorich, J; Speyer, J; Wadler, S; Wallach, RC; Wright, J | 1 |
| Bissett, D; Cassidy, J; de Bono, JS; Fraier, D; Magnè, ML; Main, M; Muirhead, F; Pellizzoni, C; Porro, MG; Robson, L; Speed, W; Spinelli, R; Twelves, C | 1 |
| Hütter, G; Keilholz, U; Krebs, P; Schmittel, A; Schulze, K; Thiel, E | 1 |
| Goto, K; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsui, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Nokihara, H; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Sugiura, T; Tamura, T; Yamamoto, N; Yoshida, K | 1 |
| Fukuda, M; Inoue, Y; Kasai, T; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsurutani, J | 1 |
| Fushiki, H | 1 |
| Assadourian, S; de Jong, FA; de Jonge, MJ; Dumez, H; Eskens, FA; Lefebvre, P; Sanderink, GJ; Selleslach, J; Soepenberg, O; Sparreboom, A; Ter Steeg, J; Thomas, J; van Oosterom, AT; van Schaik, RH; Verweij, J | 1 |
| Chatterjee, A; Digumarti, R; Jiwatani, S; Katneni, K; Mamidi, RN; Mullangi, R; Srinivas, ML; Srinivas, NR; Surath, A; Uppalapati, S; Upreti, VV | 1 |
| Berghorn, E; Centeno, B; Daud, A; Deconti, RC; Derderian, J; Hausheer, F; Liu, Z; Munster, P; Sullivan, D; Sullivan, P; Urbas, P; Valkov, N | 1 |
| Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G | 1 |
| Büscher, C; Fähndrich, S; Fietkau, R; Klautke, G; Semrau, S; Virchow, C | 1 |
| Harita, S; Hotta, K; Kiura, K; Kuyama, S; Okimoto, N; Segawa, Y; Shinkai, T; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N | 1 |
| Fukuoka, M; Hirashima, T; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Nakagawa, K; Takada, M; Tsukada, H; Yana, T | 1 |
| Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL | 1 |
| Beijnen, JH; Davies, BE; Koier, I; Maes, RA; Rodenhuis, S; Rosing, H; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Chen, TL; Donehower, RC; Ettinger, DS; Grochow, LB; Lubejko, BG; Rock, MK; Rowinsky, EK; Sartorius, SE | 1 |
| Hata, K; Higuchi, M; Kajino, T; Shibata, N | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Huber, MH; Kane, J; Kemp, BL; Kurie, JM; Lee, JJ; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Raber, MN; Robinson, RA; Shin, DM | 1 |
| Beijnen, JH; Creemers, GJ; Davies, BE; de Boer-Dennert, M; Maes, RA; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ; Verweij, J | 1 |
| Fossella, FV; Glisson, BS; Hong, WK; Lee, JS; Murphy, WK; Perez-Soler, R; Shin, DM | 1 |
| Alvarez, RD; Armstrong, DK; Barker, SD; Bookman, MA; Fleming, GF; Horowitz, IR; McGuire, WP; O'Reilly, S; Ozols, RF; Rowinsky, EK; Schilder, RJ; Walczak, JR | 1 |
| Boku, N; Fujii, T; Fukuda, H; Kondo, H; Muro, K; Oda, Y; Ohtsu, A; Oka, M; Ono, H; Saito, D; Shimada, Y; Shirao, K; Watanabe, Y; Yamao, T; Yokoyama, T; Yoshida, S | 1 |
| Abigerges, D; Armand, JP; Bugat, R; Catimel, G; Extra, JM; Hérait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Suc, E | 1 |
| Broom, C; Burris, HA; Creemers, GJ; Eckardt, JR; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; Verweij, J; Von Hoff, DD | 1 |
| Creemers, GJ; de Boer-Dennert, M; DePee, S; Gerrits, CJ; Harteveld, M; Planting, AS; Pritchard, JF; Schellens, JH; Verweij, J; Wissel, P | 1 |
| Berkery, R; Harrison, J; Kelsen, DP; Kemeny, NE; Saltz, LB; Tong, W | 1 |
| Edwards, CL; Ende, K; Freedman, RS; Giovanella, BC; Kavanagh, JJ; Kudelka, AP; Natelson, EA; Stehlin, JS; Verschraegen, CF | 1 |
| Baker, SD; Burke, TG; Burris, HA; DePee, S; Eckardt, JR; Eckhardt, SG; Fields, S; Kuhn, JG; Kunka, R; Littlefield, D; Rodriguez, G; Rothenberg, ML; Rowinsky, EK; Smith, L; Thurman, A; Von Hoff, DD; Warner, DL; White, L; Wissel, P | 1 |
| Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL | 1 |
| Bartel, S; Bharti, A; Hurwitz, S; Levy, S; Lynch, C; Rosowsky, A; Rubin, E; Toppmeyer, D; Trites, D; Wood, V | 1 |
| Beijnen, JH; Herben, VM; Hillebrand, MJ; Lieverst, J; Porro, MG; Schellens, JH; Schoemaker, NE; Schot, M; ten Bokkel Huinink, WW; van Gijn, R | 1 |
| Dallaire, BK; de Jonge, MJ; Gelderblom, AH; Loos, WJ; Planting, AS; Punt, CJ; Sparreboom, A; van Beurden, V; van der Burg, ME; van Maanen, LW; Verweij, J; Wagener, DJ | 1 |
| Kamura, T; Sugiyama, T; Ushijima, K | 1 |
| Coyle, J; De Jager, RL; Drengler, R; Eckhardt, SG; Geyer, CE; Hammond, LA; Johnson, TR; Rizzo, J; Rowinsky, EK; Schwartz, G; Smetzer, L; Tolcher, A; Von Hoff, DD | 1 |
| Coyle, J; De Jager, R; Ducharme, MP; Dumas, P; Hoff, PM; Lassere, Y; Lee, JJ; Pazdur, R; Royce, ME | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Erlichman, C; Goldberg, RM; Kaufmann, SH; Okuno, SH; Pitot, HC; Rubin, J; Sloan, J | 1 |
| Fujii, H; Igarashi, T; Itoh, K; Minami, H; Oguma, T; Sasaki, Y; Tamanoi, K | 1 |
| Coyle, J; De Jager, RL; Ducharme, MP; Hollywood, E; Ilson, D; Kelsen, D; Kemeny, N; Kleban, S; O'Reilly, E; Saltz, LB; Schwartz, GK; Sharma, S | 1 |
| Chin, K; Goto, M; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yamao, T | 1 |
| Aiba, K; Fujiwara, K; Horikoshi, N; Ito, Y; Mizunuma, N; Omachi, K; Saotome, T; Sugiyama, K; Takahashi, S | 1 |
| Bos, AM; Cameron, T; de Jonge, MJ; de Vries, EG; Groen, HJ; Hamilton, M; Kehrer, DF; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
| Chamberlain, MC | 1 |
| Cohen, MH; Creaven, PJ; Hansen, HH; Muggia, FM; Selawry, OS | 1 |
4 review(s) available for camptothecin and Thrombopenia
| Article | Year |
|---|---|
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting | 2017 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Irinotecan; Leucovorin; Leukopenia; Nausea; Stomatitis; Thrombocytopenia; Vomiting | 2003 |
[Kampo therapy for side effects of gynecologic carcinomatous chemotherapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cytokines; Drugs, Chinese Herbal; Female; Genital Neoplasms, Female; Hematopoiesis; Humans; Irinotecan; Leukopenia; Lymphocyte Activation; Mice; Nausea; Peripheral Nervous System Diseases; Phytotherapy; Thrombocytopenia; Vomiting; Weight Loss | 2004 |
[New regimens for the treatment of gynecologic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 2000 |
57 trial(s) available for camptothecin and Thrombopenia
| Article | Year |
|---|---|
A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer.
Topics: Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Response Evaluation Criteria in Solid Tumors; Retreatment; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma; Diarrhea; Disease-Free Survival; DNA-Binding Proteins; Endometrial Neoplasms; Endonucleases; Female; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Survival Rate; Thrombocytopenia; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2018 |
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrroles; Thrombocytopenia; Treatment Outcome | 2013 |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia | 2014 |
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Leucovorin; Logistic Models; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index; Thrombocytopenia; Valine; Vomiting | 2014 |
Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Feasibility Studies; Febrile Neutropenia; Female; Humans; Hypokalemia; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Small Cell Lung Carcinoma; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2015 |
Gemcitabine, irinotecan and celecoxib in patients with biliary cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Celecoxib; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2009 |
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Colitis; Dacarbazine; Diarrhea; Female; Humans; Irinotecan; Male; Neutropenia; Pneumonia; Recurrence; Remission Induction; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Thrombocytopenia; Young Adult | 2009 |
Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Alanine Transaminase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Positron-Emission Tomography; Survival Rate; Thrombocytopenia; Tomography, X-Ray Computed | 2011 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Rate; Thrombocytopenia | 2012 |
Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Thrombocytopenia; Treatment Outcome | 2012 |
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Severity of Illness Index; Small Cell Lung Carcinoma; Thrombocytopenia; Treatment Outcome | 2012 |
[A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia | 2012 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2013 |
Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival; Thrombocytopenia | 2002 |
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
[A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Thrombocytopenia | 2003 |
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia | 2003 |
Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2004 |
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT).
Topics: Acrylamides; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Sepsis; Thrombocytopenia | 2004 |
Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiography; Thrombocytopenia; Treatment Outcome | 2004 |
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2004 |
Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Thrombocytopenia | 2004 |
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Capsules; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; Dietary Fats; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2005 |
Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study.
Topics: Adult; Aged; Camptothecin; Capsules; Chemistry, Pharmaceutical; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Thrombocytopenia | 2005 |
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Topics: Adult; Aged; Anemia; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Fatigue; Female; HL-60 Cells; Humans; Male; Melanoma; Middle Aged; Nausea; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2005 |
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting | 2005 |
Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Disease Progression; Dose Fractionation, Radiation; Esophagitis; Feasibility Studies; Female; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pneumonia; Radiotherapy, Adjuvant; Remission Induction; Thrombocytopenia; Treatment Outcome | 2006 |
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2007 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neutropenia; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Half-Life; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Recombinant Proteins; Remission Induction; Thrombocytopenia | 1994 |
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia; Topotecan; United States | 1995 |
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan | 1995 |
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Feasibility Studies; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Muscle Cramp; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting | 1994 |
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Thrombocytopenia; Topotecan; Treatment Outcome | 1996 |
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
Topics: Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Ovarian Neoplasms; Thrombocytopenia; Topoisomerase I Inhibitors; Topotecan | 1996 |
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Vomiting | 1997 |
Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Thrombocytopenia | 1997 |
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1997 |
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Half-Life; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan | 1997 |
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Fatigue; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Stomatitis; Thrombocytopenia; Topoisomerase I Inhibitors; Treatment Outcome; Vomiting | 1997 |
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Thrombocytopenia; Treatment Outcome | 1997 |
A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors | 1998 |
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1998 |
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1995 |
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Colloids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Female; Hematopoiesis; Humans; Infusions, Intravenous; Lactones; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia | 1999 |
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Least-Squares Analysis; Likelihood Functions; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacokinetics; Thrombocytopenia | 1999 |
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting | 2000 |
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Thrombocytopenia | 2001 |
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 2001 |
Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2001 |
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors | 2001 |
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Survival Rate; Thrombocytopenia | 2001 |
Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2002 |
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Thrombocytopenia | 2002 |
Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Salvage Therapy; Supratentorial Neoplasms; Thrombocytopenia | 2002 |
21 other study(ies) available for camptothecin and Thrombopenia
| Article | Year |
|---|---|
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; Camptothecin; Diarrhea; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Thrombocytopenia; Vomiting | 2022 |
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Databases, Factual; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Logistic Models; Male; Middle Aged; Nausea; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Sex Factors; Stomatitis; Thrombocytopenia; Vomiting | 2021 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia | 2017 |
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Health Status; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia | 2018 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer.
Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Hypertension, Portal; Immunohistochemistry; Leucovorin; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platelet Endothelial Cell Adhesion Molecule-1; Splenomegaly; Thrombocytopenia; Tomography, X-Ray Computed | 2013 |
Irinotecan-induced immune thrombocytopenia.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Colonic Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Platelet Count; Thrombocytopenia | 2014 |
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2014 |
Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Compounding; Drug Synergism; Humans; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Nitrophenols; Piperazines; Sulfonamides; Thrombocytopenia | 2014 |
[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Incidence; Irinotecan; Leucovorin; Male; Middle Aged; Polymorphism, Genetic; Thrombocytopenia | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Gamma Rays; Humans; Hysterectomy; Injections, Intravenous; Irinotecan; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Survival Analysis; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms | 2016 |
Acute thrombocytopenia: an unusual complication occurring after drug-eluting microspheres transcatheter hepatic chemoembolization.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Agents; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Follow-Up Studies; Humans; Irinotecan; Leukocyte Count; Liver Neoplasms; Male; Microspheres; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platelet Count; Sigmoid Neoplasms; Thrombocytopenia | 2011 |
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Feasibility Studies; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Incidence; Infusions, Intravenous; Irinotecan; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Patient Selection; Polymorphism, Genetic; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Surveys and Questionnaires; Thrombocytopenia | 2011 |
Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery.
Topics: Abdominal Neoplasms; Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Desmoplastic Small Round Cell Tumor; Erythrocyte Transfusion; Feasibility Studies; Humans; Hyperthermia, Induced; Interferons; Irinotecan; Liver Neoplasms; Male; Pelvic Neoplasms; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Retrospective Studies; Temozolomide; Thrombocytopenia; Vinblastine; Vinorelbine; Young Adult | 2012 |
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Rectal Neoplasms; Retrospective Studies; Survival Analysis; Thrombocytopenia; Vomiting, Anticipatory | 2003 |
[Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Thrombocytopenia | 1996 |
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Topotecan | 1996 |
Irinotecan-induced immune thrombocytopenia.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Thrombocytopenia | 1998 |
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.
Topics: Camptothecin; Cystitis; Humans; Leukocyte Count; Leukopenia; Neoplasms; Thrombocytopenia | 1972 |